Chemistry:Motexafin lutetium
From HandWiki
| |
| Names | |
|---|---|
| Other names
Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| DrugBank | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C52H72LuN5O14 | |
| Molar mass | 1166.136 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Motexafin lutetium is a texaphyrin, developed by Pharmacyclics Inc. (proposed trade names Lutrin, Antrin and Optrin)
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]
It is photoactivated by 732 nm light which allows greater depth of penetration.[2]
Clinical trials
Phase II clinical trials were in progress in 1999.[3]
A phase I trial for prostate cancer reported in 2009.[4]
As of 2017, this drug is no longer being developed.[5]
See also
References
- ↑ Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease , 2002
- ↑ https://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
- ↑ Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT , 1999
- ↑ Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM et al. (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMID 18676760.
- ↑ Kirkpatrick, DL; Powis, Garth (2017). "Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling". Antioxidants & Redox Signaling 26 (6): 262-273. doi:10.1089/ars.2016.6633. PMID 26983373.
 |  |
